Seres Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit
September 22 2020 - 7:00AM
Business Wire
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it
will present a corporate overview at the Jefferies Next Generation
IBD Therapeutics Summit on Wednesday, September 23 at 8:00 a.m.
E.T.
A webcast of the presentation will be available under the
“Investors and Media” section of Seres’ website and will be
archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome
therapeutics platform company developing a novel class of
multifunctional bacterial consortia that are designed to
functionally interact with host cells and tissues to treat disease.
Seres’ SER-109 program achieved the first-ever positive pivotal
clinical results for a targeted microbiome drug candidate and has
obtained Breakthrough Therapy and Orphan Drug designations from the
FDA. The SER-109 program is being advanced for the treatment of
recurrent C. difficile infection and has potential to become a
first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287
program has obtained Fast Track and Orphan Drug designations from
the FDA and is being evaluated in a Phase 2b study in patients with
active mild-to-moderate ulcerative colitis. Seres is developing
SER-401 in a Phase 1b study in patients with metastatic melanoma,
SER-301 for ulcerative colitis and SER-155 to prevent mortality due
to gastrointestinal infections, bacteremia and graft versus host
disease. For more information, please visit
www.serestherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200922005219/en/
PR Contact Lisa Raffensperger
lisa@tenbridgecommunications.com IR Contact Carlo Tanzi,
Ph.D. ctanzi@serestherapeutics.com
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Sep 2023 to Sep 2024